Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew


IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2018: 156.09

Open Access
Online
ISSN
2391-5463
See all formats and pricing
More options …
Volume 3, Issue 3

Issues

Volume 10 (2015)

Assessment of chemotherapy-induced anemia in children with cancer

Antonio Ruggiero / Giorgio Attinà / Melina Haber / Paola Coccia / Ilaria Lazzareschi / Riccardo Riccardi
Published Online: 2008-07-10 | DOI: https://doi.org/10.2478/s11536-008-0049-3

Abstract

Anemia is a common cause of co-morbidity in children with cancer. We reviewed a series of 124 children with non-metastatic cancer to assess the relationship between chemotherapy intensity, severe anemia, and frequency of transfusion. In more than 60% of children who received intensive chemotherapy, transfusions were prescribed compared to 38% and 21% of children treated with standard and mild chemotherapy, respectively. In conclusion, our data suggest that the intensity and duration of chemotherapy constitute important factors in determining the onset of anemia.

Keywords: Anemia; Chemotherapy-induced anemia; Children; Cancer; Transfusion

  • [1] Leitgeb C., Pecherstorfer M., Fritz E., Ludwig H., Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin, Cancer, 1994, 73(10), 2535–42 http://dx.doi.org/10.1002/1097-0142(19940515)73:10<2535::AID-CNCR2820731014>3.0.CO;2-5CrossrefGoogle Scholar

  • [2] Corazza F., Beguin Y., Bergmann P., Andre M., Ferster A., Devalck C., Fondu P., Buyse M., Sariban E., Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production, Blood, 1998, 92(5),1793–8 PubMedGoogle Scholar

  • [3] Lai J.S., Cella D., Kupst M.J., Holm S., Kelly M.E., Bode R.K., Goldman S., Measuring fatigue for children with cancer: development and validation of the pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F), J. Pediatr. Hematol. Oncol., 2007, 29(7), 471–9 http://dx.doi.org/10.1097/MPH.0b013e318095057aWeb of ScienceCrossrefGoogle Scholar

  • [4] Jelkmann W., Developments in the therapeutic use of erythropoiesis stimulating agents, Br. J. Haematol., 2008, 141(3), 287–97 PubMedGoogle Scholar

  • [5] Dainiak N., Kulkarni V., Howard D., Kalmanti M., Dewey M.C., Hoffman R., Mechanisms of abnormal erythropoiesis in malignancy, Cancer, 1983, 51(6), 1101–6 http://dx.doi.org/10.1002/1097-0142(19830315)51:6<1101::AID-CNCR2820510622>3.0.CO;2-GCrossrefGoogle Scholar

  • [6] Ludwig H., Fritz E., Anemia in cancer patients, Semin. Oncol. 1998, 25(3 Suppl 7), 2–6 Google Scholar

  • [7] Ludwig H., Epoetin in cancer-related anaemia, Nephrol. Dial. Transplant., 1999, 14(S2), 85–92 http://dx.doi.org/10.1093/ndt/14.suppl_2.85CrossrefGoogle Scholar

  • [8] Mercadante S., Gebbia V., Marrazzo A., Filosto S., Anaemia in cancer: pathophysiology and treatment, Cancer Treat. Rev., 2000, 26(4), 303–11 http://dx.doi.org/10.1053/ctrv.2000.0181CrossrefGoogle Scholar

  • [9] Shankar A.G., The role of recombinant erythropoietin in childhood cancer, Oncologist,. 2008, 13(2),157–66 http://dx.doi.org/10.1634/theoncologist.2007-0126CrossrefWeb of ScienceGoogle Scholar

  • [10] Means R.T. Jr, Krantz S.B., Progress in understanding the pathogenesis of the anemia of chronic disease, Blood, 1992, 80(7),1639–47 Google Scholar

  • [11] Groopman J.E., Itri L.M., Chemotherapy-induced anemia in adults: incidence and treatment, J. Natl. Cancer Inst., 1999, 91(19), 1616–34. Erratum in: J. Natl. Cancer Inst., 2000, 92(6), 497 http://dx.doi.org/10.1093/jnci/91.19.1616CrossrefGoogle Scholar

  • [12] Ruggiero A., Riccardi R., Interventions for anemia in pediatric cancer patients, Med. Pediatr. Oncol., 2002,39(4),451–4 http://dx.doi.org/10.1002/mpo.10184CrossrefGoogle Scholar

  • [13] Miller C.B., Jones R.J., Piantadosi S., Abeloff M.D., Spivak J.L., Decreased erythropoietin response in patients with the anemia of cancer, N. Engl. J. Med., 1990, 322(24), 1689–92 CrossrefGoogle Scholar

  • [14] Adamson J.W., Ludwig H., Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer, Oncology, 1999, 56(1), 46–53 http://dx.doi.org/10.1159/000011929CrossrefGoogle Scholar

  • [15] Schapira L., Antin J.H., Ransil B.J., Antman K.H., Eder J.P., McGarigle C.J., Goldberg M.A., Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy, Blood, 1990, 76(11), 2354–9 Google Scholar

  • [16] Marc-Berad P., Blay J.K., Schell M., Buclon M., Demaret C., Ray-Coquard I., Risk model predictive of severe anemia requiring RBC transfusion after chemotherapy in pediatric solid tumor patients, J. Clin. Oncol., 2003, 21, 4235–9 http://dx.doi.org/10.1200/JCO.2003.09.121CrossrefGoogle Scholar

  • [17] Cascinu S., Fedeli A., Luzi Fedeli S., Catalano G., Cisplatin-associated anemia treated with subcutaneous erythropoietin. A pilot study, Br. J. Cancer, 1993, 67, 156–58 CrossrefGoogle Scholar

About the article

Published Online: 2008-07-10

Published in Print: 2008-09-01


Citation Information: Open Medicine, Volume 3, Issue 3, Pages 341–345, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-008-0049-3.

Export Citation

© 2008 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in